To identify whether expression of UBE2C affects survival outcomes in patients with cholangiocarcinoma, Kaplan–Meier analysis indicated that UBE2C high expression was markedly associated with poorer overall survival (Fig. 3A; p-value = 0.0013), disease-specific survival (Fig. 3B; p-value = 0.0004), local recurrence-free survival (Fig. 3C; p-value < 0.0001), and metastasis-free survival (Fig. 3D; p-value = 0.0008). The gene discussed is UBE2C; the disease is cholangiocarcinoma.